Vitrolife AB (publ) EBIT

The latest EBIT for VITR.ST is $-4.8B as of June 2026. That compares with $690M in the prior-year period — down 797.4% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Vitrolife AB (publ)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, VITR.ST's EBIT moved from $690M to $-4.8B — a 797.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vitrolife AB (publ)'s operating scale or balance-sheet position.

Against its sector companies, VITR.ST currently prints $-4.8B for EBIT, while the sector average sits near $2.6T. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at Vitrolife AB (publ)'s growth, margins, and balance sheet.

A EBIT figure of $-4.8B for VITR.ST is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting VITR.ST's EBIT ($-4.8B), review year-over-year change from $690M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.